RENALYTIX AI
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, and patient stratification for drug clinical trials. RenalytixAI’s technology platform will draw from distinct sources of patient data, including large electronic health records, p... redictive blood-based biomarkers, and other genomic information for analysis by learning computer algorithms. RenalytixAI intends to build a deep, unique pool of kidney disease-related data for different AI-enabled applications designed to improve predictive capability and clinical utility over time.
RENALYTIX AI
Industry:
Artificial Intelligence Biotechnology Health Care Health Diagnostics Medical Device
Founded:
2018-01-01
Address:
Penarth, Vale Of Glamorgan, The, United Kingdom
Country:
United Kingdom
Website Url:
http://www.renalytix.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0)20 7933 8780
Email Addresses:
[email protected]
Total Funding:
76.41 M USD
Technology used in webpage:
SPF LetsEncrypt Domain Not Resolving Microsoft Exchange Online Office 365 Mail IPv6 ReCAPTCHA Microsoft Azure DNS Google Google Cloud
Similar Organizations
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Current Employees Featured
Founder
Stock Details
Investors List
Thomas McLain
Thomas McLain investment in Post-IPO Equity - Renalytix AI
Thomas McLain
Thomas McLain investment in Post-IPO Debt - Renalytix AI
Ann E. Berman
Ann E. Berman investment in Post-IPO Debt - Renalytix AI
Christopher Mills
Christopher Mills investment in Post-IPO Debt - Renalytix AI
Timothy J. Scannell
Timothy J. Scannell investment in Post-IPO Debt - Renalytix AI
Ann E. Berman
Ann E. Berman investment in Post-IPO Equity - Renalytix AI
Timothy J. Scannell
Timothy J. Scannell investment in Post-IPO Equity - Renalytix AI
Christopher Mills
Christopher Mills investment in Post-IPO Equity - Renalytix AI
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-07 | Renalytix Appoints Jean M. Casner as Chief Human Resources Officer |
Official Site Inspections
http://www.renalytix.com
- Host name: 101.111.198.104.bc.googleusercontent.com
- IP address: 104.198.111.101
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Renalytix AI"
Renalytix - Renalytix
With our KidneyIntelX™ technology, we help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. …See details»
Company Profile | Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower …See details»
Journey - Renalytix
Renalytix initiates KidneyIntelX Testing at Mount Sinai, with its first live EHR Integration. AUGUST: Renalytix announces partnership with Astra-Zeneca, teaming up to improve CKD treatments and outcomes. Renalytix files …See details»
Renalytix - Org Chart, Teams, Culture & Jobs - The Org
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health. It takes less than ten minutes to set up your company page. …See details»
Audited Full Year Fiscal 2024 Results - investors.renalytix.com
Nov 21, 2024 · Renalytix plc (" Renalytix" or the "Company ") Audited Full Year Fiscal 2024 Results LONDON and NEW YORK, 21 November 2024 - Renalytix plc (LSE: RENX) (OTCQB: …See details»
KidneyIntelX and kidneyintelX.dkd - Healthier kidneys …
Today, the KidneyIntelX test platform uses our proprietary bioprognostic™ methodology to identify adult patients with type 2 diabetes and chronic kidney disease (stages 1-3b) who are at increased risk for a progressive decline in …See details»
Renalytix - LinkedIn
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the founder and global leader in the new field of bioprognosis™ for kidney health. We’ve engineered a proprietary solution that successfully enables...See details»
Renalytix AI - Crunchbase Company Profile & Funding
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney health. View contacts for Renalytix AI to access new leads and connect with decision-makers. Legal Name Renalytix AI plc.See details»
Renalytix Reports Financial Results for First Quarter of …
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk …See details»
Renalytix AI plc (“RenalytixAI” or the “Company”) Full Year Report
Oct 26, 2024 · RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical …See details»
Update on FDA De Novo Authorization Process - Renalytix
Mar 21, 2023 · LONDON and SALT LAKE CITY, March 21, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the review process with the Food and Drug …See details»
Renalytix plc Reports Financial Results for First Quarter of Fiscal ...
Nov 20, 2024 · Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the …See details»
Renalytix Reports Full Year Fiscal 2022 Results
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables …See details»
Renalytix Releases Annual Report and AGM Details
2 days ago · Renalytix AI (GB:RENX) has released an update. Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter …See details»
Renalytix Reports Financial Results for Q3 FY2024 | Renalytix
Mar 31, 2024 · Renalytix (NASDAQ: RNLX) (LSE: RENX) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the …See details»
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX …
RAPID, in combination with unique contracted access to large medical center patient cohorts, enables KidneyIntelX™ improvements for its bioprognostic™ methodology and therapeutic …See details»
Renalytix Plc (RNLXY)
Find the latest Renalytix Plc (RNLXY) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
FDA grants Breakthrough Device designation to KidneyIntelX™
May 2, 2019 · Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device …See details»
From Bench to Bedside: Predicting Who Will Develop Chronic …
To shift that conversation and prevent CKD from becoming the fifth leading cause of death worldwide by 2040, Dr. Coca co-founded Renalytix with Girish Nadkarni, MD, the Irene and Dr. …See details»
Why - Renalytix
With early stage assessment of risk of disease progression, treatment insights, and patient engagement, it’s possible to slow it down. And hopefully, one day, stop it altogether. Get …See details»